Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Premixed Lyumjev
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Premixed Lyumjev is a combination pharmaceutical product consisting of Lyumjev (a fast-acting insulin) and micro-doses of glucagon. It is being investigated for its potential to accelerate the absorption of insulin and enhance its effect on whole-body glucose consumption in patients with type 1 diabetes. The glucagon component is hypothesized to increase local subcutaneous blood flow at the injection site, thereby facilitating faster absorption of the co-administered insulin.
- Other names
- Glucagon/Lyumjev solutionPremixed Glucagon/Insulin Solution
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on Premixed Lyumjev.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Premixed Lyumjev.